08:47 AM EDT, 04/22/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Monday that it has signed an in-license agreement with Cornell University to expedite the development of investigational gene therapy candidate LX2006 to treat Friedreich ataxia cardiomyopathy.

Under the deal, Lexeo said it has acquired certain rights, including rights to current and future data generated in an ongoing investigator-initiated phase 1A trial of AAVrh.10hFXN, which Lexeo refers to as LX2006, to treat FA cardiomyopathy. Financial terms were not disclosed.